Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
178 participants
INTERVENTIONAL
2025-04-25
2026-08-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Effectiveness of Remote Ischemic Conditioning Combined With Intravenous Thrombolysis in Treating Acute Ischemic Stroke
NCT04027621
Safety and Efficacy of Remote Ischemic Conditioning Combined With Intravenous Thrombolysis for Acute Ischemic Stroke
NCT04980625
Safety and Efficacy of Remote Ischemic Conditioning for Acute Ischemic Stroke
NCT04980651
Safety and Efficacy Study of Remote Ischemic Conditioning Combined With Endovascular Thrombectomy for Acute Ischemic Stroke Due to Large Vessel Occlusion of Anterior Circulation
NCT04977869
Effects of Transcranial Magnetic Stimulation After Endovascular Treatment for Acute Ischemic Stroke
NCT06639360
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
iTBS
Patients are treated with intermittent theta burst stimulation (iTBS).
intermittent theta burst stimulation
The iTBS delivered to the ipsilesional primary motor cortex (M1) at 80% resting motor threshold (RMT). Each session consists of 600 pulses (3-minute trains of 50 Hz triplets repeated every 10 seconds, twice daily with a 5-minute interval), administered for 7 consecutive days starting within 6 hours post-randomization.
sham-iTBS
Patients are treated with sham intermittent theta burst stimulation (sham-iTBS).
sham intermittent theta burst stimulation
Sham-iTBS is performed in the same way as the treatment group but uses 20% RMT.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
intermittent theta burst stimulation
The iTBS delivered to the ipsilesional primary motor cortex (M1) at 80% resting motor threshold (RMT). Each session consists of 600 pulses (3-minute trains of 50 Hz triplets repeated every 10 seconds, twice daily with a 5-minute interval), administered for 7 consecutive days starting within 6 hours post-randomization.
sham intermittent theta burst stimulation
Sham-iTBS is performed in the same way as the treatment group but uses 20% RMT.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 2\) Acute ischemic stroke caused by occlusion of the anterior circulation large vessels (internal carotid artery, M1 or M2 segment of the middle cerebral artery), verified by CTA or DSA.
* 3\) Mechanical thrombectomy (MT) performed within 24 hours of symptom onset.
* 4\) Successful Reperfusion: Post-MT eTICI score ≥ 2b.
* 5\) NIHSS score 5-25 at 24 hours post-MT, with ≥2 points in at least one limb.
Exclusion Criteria
* 2\) PH2-type intracranial hemorrhage on brain CT post-MT.
* 3\) Patients who underwent intracranial stent placement during MT.
* 4\) Contraindications to iTBS: History of epilepsy or seizures, implanted cardiac pacemakers, cochlear implants, or other electronic/magnetic-sensitive devices.
* 5\) Severe consciousness impairment, cognitive dysfunction, or psychiatric disorders preventing compliance with iTBS.
* 6\) Expected survival \<3 months due to other medical conditions or inability to complete follow-up for any reason.
* 7\) Participation in another interventional study.
* 8\) Any other condition deemed unsuitable for enrollment by the investigator.
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yi Yang
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yi Yang
Vice President of First Hospital of Jilin University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First Hospital of Jilin University
Changchun, Jilin, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
iTBS-ACT
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.